Cargando…

Potential Inhibitors of Monkeypox Virus Revealed by Molecular Modeling Approach to Viral DNA Topoisomerase I

The monkeypox outbreak has become a global public health emergency. The lack of valid and safe medicine is a crucial obstacle hindering the extermination of orthopoxvirus infections. The identification of potential inhibitors from natural products, including Traditional Chinese Medicine (TCM), by mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xiaopeng, An, Sanqi, Chu, Jiemei, Liang, Bingyu, Liao, Yanyan, Jiang, Junjun, Lin, Yao, Ye, Li, Liang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919579/ https://www.ncbi.nlm.nih.gov/pubmed/36771105 http://dx.doi.org/10.3390/molecules28031444

Ejemplares similares

Genome-Wide Profiling Reveals Alternative Polyadenylation of Innate Immune-Related mRNA in Patients With COVID-19
por: An, Sanqi, et al.
Publicado: (2021)

Weighted gene co-expression network analysis revealed T cell differentiation associated with the age-related phenotypes in COVID-19 patients
por: Lin, Yao, et al.
Publicado: (2023)

Comparison of ARIMA, ES, GRNN and ARIMA–GRNN hybrid models to forecast the second wave of COVID-19 in India and the United States
por: Wang, Gang, et al.
Publicado: (2021)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA–topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts
por: Dexheimer, Thomas S., et al.
Publicado: (2008)

Different Modes of Cell‐killing Action between DNA Topoisomerase I and II Inhibitors Revealed by Kinetic Analysis
por: Inaba, Makoto, et al.
Publicado: (1994)

Identification and analysis of lncRNA, microRNA and mRNA expression profiles and construction of ceRNA network in Talaromyces marneffei-infected THP-1 macrophage
por: Li, Yueqi, et al.
Publicado: (2021)

Viral origin of eukaryotic type IIA DNA topoisomerases
por: Guglielmini, Julien, et al.
Publicado: (2022)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
por: Grossman, Scott, et al.
Publicado: (2023)

Bacterial topoisomerase I and topoisomerase III relax supercoiled DNA via distinct pathways
por: Terekhova, Ksenia, et al.
Publicado: (2012)

Systematic analysis of clinical relevance and molecular characterization of m(6)A in COVID-19 patients
por: An, Sanqi, et al.
Publicado: (2022)

Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products
por: Xin, Lan-Ting, et al.
Publicado: (2017)

Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae
por: Valenzuela, Myriam V., et al.
Publicado: (2020)

Novel bivalent securinine mimetics as topoisomerase I inhibitors
por: Hou, Wen, et al.
Publicado: (2017)

The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation
por: Zhao, Wuli, et al.
Publicado: (2015)

Adaptation of topoisomerase I paralogs to nuclear and mitochondrial DNA
por: Rosa, Ilaria Dalla, et al.
Publicado: (2009)

Immunodetection of human topoisomerase I-DNA covalent complexes
por: Patel, Anand G., et al.
Publicado: (2016)

Inhibition of cytotoxic T lymphocyte-induced target cell DNA fragmentation, but not lysis, by inhibitors of DNA topoisomerases I and II
Publicado: (1992)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion
por: Bax, Benjamin D., et al.
Publicado: (2019)

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan
por: Meisenberg, Cornelia, et al.
Publicado: (2017)

Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity
Publicado: (1996)

On the viability of Escherichia coli cells lacking DNA topoisomerase I
por: Stockum, Anna, et al.
Publicado: (2012)

The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I
por: Gentry, Amanda C., et al.
Publicado: (2011)

Design, Synthesis, and Biological Evaluation of O-2-Modified Indenoisoquinolines as Dual Topoisomerase I–Tyrosyl-DNA Phosphodiesterase I Inhibitors
por: Lv, Peng-Cheng, et al.
Publicado: (2014)

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II
por: Xu, Huanli, et al.
Publicado: (2016)

Enhanced Signaling Through the TLR9 Pathway Is Associated With Resistance to HIV-1 Infection in Chinese HIV-1–Exposed Seronegative Individuals
por: Jiang, Junjun, et al.
Publicado: (2020)

CK2-Mediated Hyperphosphorylation of Topoisomerase I Targets Serine 506, Enhances Topoisomerase I–DNA Binding, and Increases Cellular Camptothecin Sensitivity
por: Bandyopadhyay, Keya, et al.
Publicado: (2012)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
por: Gerrits, C. J., et al.
Publicado: (1997)

Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes
por: Chae, Sieun, et al.
Publicado: (2018)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

DNA topoisomerase I and II expression in drug resistantgerm cell tumours
por: Berney, D M, et al.
Publicado: (2002)

Transcription facilitated genome-wide recruitment of topoisomerase I and DNA gyrase
por: Ahmed, Wareed, et al.
Publicado: (2017)

Why Should DNA Topoisomerase I Have a Scaffold Activity?
por: Di Felice, Francesca, et al.
Publicado: (2021)

Two type I topoisomerases maintain DNA topology in human mitochondria
por: Menger, Katja E, et al.
Publicado: (2022)

Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions
por: Busatto, Franciele Faccio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m2p1o2th1si0nj5v2efmqpvb8i